Chairman Wu Ying of Yangling Metron New Material (300861.SZ) retires and resigns.
Meichang Group (300861.SZ) Announcement: The company has received a written resignation letter from Wu Ying, the chairman of the third session of the company's board of directors.
Yangling Metron New Material (300861.SZ) announced that the company has received a written resignation letter from Mr. Wu Ying, the Chairman of the third board of directors. Due to reaching the statutory retirement age and considering the need for talent development and long-term growth of the company, Mr. Wu Ying has applied to resign from his position as Director (Chairman) of Yangling Metron New Material and as a member of various special committees of the board of directors, as well as from all positions within the company's subsidiary companies. Upon resigning as Chairman of the company, Mr. Wu Ying is considered to have also resigned as the legal representative. After resigning from his position as Director (Chairman) of Yangling Metron New Material, Mr. Wu Ying will no longer hold any positions within Yangling Metron New Material and its subsidiary companies.
Related Articles

HK Stock Market Move | INNOVENT BIO(01801) rose more than 4%, Marsdek peptide recently approved for listing, commercialization is imminent.

HK Stock Market Move | DEKON AGR (02419) rose more than 5% in midday trading, empowering family farms smoothly. There is still room for improvement in the future service of live pigs.

HK Stock Market Move | AKESO (09926) rose more than 7% in early trading. The company's first dual-immune ADC drug AK146D1 entered clinical trials.
HK Stock Market Move | INNOVENT BIO(01801) rose more than 4%, Marsdek peptide recently approved for listing, commercialization is imminent.

HK Stock Market Move | DEKON AGR (02419) rose more than 5% in midday trading, empowering family farms smoothly. There is still room for improvement in the future service of live pigs.

HK Stock Market Move | AKESO (09926) rose more than 7% in early trading. The company's first dual-immune ADC drug AK146D1 entered clinical trials.

RECOMMEND

U.S. Senate Passes “Big and Beautiful” Bill, Triggering Surge in Gold Amid Soaring Deficit Concerns
02/07/2025

Declining Demand Triggers Price Drop; Photovoltaic Glass Industry May Be Preparing for a New Round of Coordinated Production Cuts
02/07/2025

Surge in Prices of Chinese-Made Goods Highlights Tariff Impact on U.S. Consumers
02/07/2025